ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva Will Acquire Allergan Generics …

by Michael McCoy
August 3, 2015 | APPEARED IN VOLUME 93, ISSUE 31

Teva Pharmaceutical Industries has abandoned its hostile takeover of Mylan and instead struck a friendly deal to acquire Allergan’s generic drugs business for $40.5 billion. The business had $6.7 billion in sales last year. Teva says the purchase will bring its sales to $26 billion, making it the world’s ninth-largest drug company and the only firm in the top 10 to focus on off-patent drugs. For its part, Allergan says selling the business will sharpen its focus on more innovative drugs. Just one day before agreeing to the sale, Allergan announced the $560 million acquisition of Naurex, an Illinois-based firm developing drugs for depression.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment